CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

• Conditions: Glioblastoma

• Registration Number: NCT03152708
• Lead Sponsor: CANbridge Life Sciences Ltd.

Brief Summary

This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-05-11
• Study First Submitted QC: 2017-05-11
• Study First Posted: 2017-05-15
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-20
• Last Update Posted: 2017-09-21
• Study Start: 2017-11-01
• Primary Completion: 2017-12-01
• Study Completion: 2017-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• Chinese nationality
• No limits on Gender and age
• First diagnosed GBM
• Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)

Exclusion Criteria

• Other types of glioma by histological diagnosis
• Tumor tissue not eligible for the central laboratory testing standard
• No enough tumor tissue for the central laboratory test

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CD95 Ligand Positive Rate	0 day

Secondary Outcome Measures

Name	Time	Method
CpG2 Positive Rate	0 day